Industry Strength Score
24/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
MEDICENNA THERAPEUTICS CORP (MDNA) Stock Price & Overview
NASDAQ:MDNA • CA58490H1073
Current stock price
0.157 USD
-0.02 (-13.16%)
At close:
0.1565 USD
0 (-0.32%)
After Hours:
The current stock price of MDNA is 0.157 USD. Today MDNA is down by -13.16%. In the past month the price decreased by -43.73%. In the past year, price decreased by -75.7%.
MDNA Key Statistics
52-Week Range0.1513 - 0.8388
Current MDNA stock price positioned within its 52-week range.
1-Month Range0.1513 - 0.31
Current MDNA stock price positioned within its 1-month range.
- Market Cap
- 10.933M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.12
- Dividend Yield
- N/A
MDNA Stock Performance
Today
-13.16%
1 Week
-39.59%
1 Month
-43.73%
3 Months
-62.59%
Longer-term
6 Months -79.29%
1 Year -75.70%
2 Years -91.65%
3 Years -95.93%
5 Years N/A
10 Years N/A
MDNA Stock Chart
MDNA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MDNA. When comparing the yearly performance of all stocks, MDNA is a bad performer in the overall market: 96.13% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
MDNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MDNA. While MDNA has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MDNA Earnings
Next Earnings DateNov 9, 2023
Last Earnings DateJul 28, 2023
PeriodQ1 / 2024
EPS Reported-CA$0.04
Revenue Reported
EPS Surprise 36.41%
Revenue Surprise %
MDNA Forecast & Estimates
11 analysts have analysed MDNA and the average price target is 2.88 USD. This implies a price increase of 1735.48% is expected in the next year compared to the current price of 0.157.
Analysts
Analysts83.64
Price Target2.88 (1734.39%)
EPS Next Y-26.16%
Revenue Next YearN/A
MDNA Financial Highlights
Over the last trailing twelve months MDNA reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 56.76% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-8.76M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.75% | ||
| ROE | -32.55% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%42.86%
Sales Q2Q%N/A
EPS 1Y (TTM)56.76%
Revenue 1Y (TTM)N/A
MDNA Ownership
Ownership
Inst Owners0.18%
Shares69.64M
Float53.17M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
MDNA Industry Overview
MDNA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 18 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
11/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
80%
Outperformed 80% of sub-industries
3 Month Rank
38%
Outperformed 38% of sub-industries
6 Month Rank
30%
Outperformed 30% of sub-industries
Industry Fundamentals & Breadth
- Members
- 18
- New Highs
- 0%
- New Lows
- 11.1%
- Average ROE
- 3.7%
- Average Profit Margin
- 3.1%
- Average Operating Margin
- 1.6%
- Average P/E
- 63.3
- Average Fwd P/E
- 9.3
- Average Debt/Equity
- 0.1
MDNA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.55 | 349.666B | ||
| AMGN | AMGEN INC | 14.72 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.58 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.75 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.62 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.48 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 11.88 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.6 | 24.944B | ||
| INCY | INCYTE CORP | 10.79 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MDNA
Company Profile
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2015-07-13. The firm is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
Company Info
IPO: 2015-07-13
MEDICENNA THERAPEUTICS CORP
2 Bloor St W 7th Floor
TORONTO ONTARIO M4S 3E2 CA
CEO: Fahar Merchant
Employees: 18
Phone: 14166485555.0
MEDICENNA THERAPEUTICS CORP / MDNA FAQ
Can you describe the business of MEDICENNA THERAPEUTICS CORP?
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2015-07-13. The firm is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
Can you provide the latest stock price for MEDICENNA THERAPEUTICS CORP?
The current stock price of MDNA is 0.157 USD. The price decreased by -13.16% in the last trading session.
Does MEDICENNA THERAPEUTICS CORP pay dividends?
MDNA does not pay a dividend.
How is the ChartMill rating for MEDICENNA THERAPEUTICS CORP?
MDNA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of MDNA stock?
MEDICENNA THERAPEUTICS CORP (MDNA) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for MDNA stock?
MEDICENNA THERAPEUTICS CORP (MDNA) currently has 18 employees.
What is the market capitalization of MDNA stock?
MEDICENNA THERAPEUTICS CORP (MDNA) has a market capitalization of 10.93M USD. This makes MDNA a Nano Cap stock.